ClinicalTrials.gg
RecruitingNCT07194265PARADIGMUpdated Jul 15, 2026

A Clinical Trial Assessing the Safety and Effectiveness of the DurAVR® THV System

An interventional study of TAVR with DurAVR® THV and TAVR with SAPIEN THV series or the Evolut THV series in Severe Aortic Stenosis and Valve-in-valve Procedures, sponsored by Anteris Technologies Ltd.. Recruiting at 1 site in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-15.

Sponsored by Anteris Technologies Ltd. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,650
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 73 studies in Aortic Valve Stenosis with a site in Denmark — 13 open to participants now, 28 under way, none of them phase 3. Aortic Valve Stenosis · Denmark.

Planned enrollment
4th of 40
1,650 · median 214
Started
2025
with 3 others
No phase
28 of 73
7 open now
Primary completion
2027-12
later than 21 of 27 live
Registered
71st of 73
by date

Among the 73 studies in Aortic Valve Stenosis with a site in Denmark, this one is the 4th largest by planned enrollment of the 40 interventional ones that give a count, is one of 4 that started in 2025, is one of 28 with no phase, reaches primary completion later than 21 of the 27 other live ones, and was the 71st registered.

Aortic Valve Stenosis

1,028 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.

Browse Aortic Valve Stenosis studies →

Open to participants now

13 of the 73 studies in Aortic Valve Stenosis with a site in Denmark are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 24 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 73 studies in Aortic Valve Stenosis with a site in Denmark, or all of them as a file.
02

Study summary

Prospective, randomized, controlled, multicenter, international study.

Up to 1054 subjects with a severe native calcific aortic stenosis who are determined by the local Heart Team to have an indication for Transcatheter Aortic Valve Replacement (TAVR), will be enrolled in the 'All Comers Randomized Cohort'. Subjects will be randomized 1:1 to receive either the DurAVR® THV System or any commercially available and approved Transcatheter Heart Valve (THV) from the SAPIEN series or the Evolut series and followed for 10 years.

After completion of the All Comers Randomized Cohort, up to 446 additional low-risk subjects will be randomized 1:1 in the 'Low Risk Randomized Continued Access Cohort'.

Up to 150 subjects with a failed surgical bioprosthesis who are deemed high surgical risk and who need valve-in-valve (ViV) TAVR will be enrolled in a separate nested registry (ViV Registry Cohort) and followed for 5 years. Subjects in the ViV Registry Cohort will only receive the DurAVR® THV.

03

Conditions studied

  • Severe Aortic Stenosis
  • Valve-in-valve Procedures

Keywords

  • tavr
  • severe calcific aortic stenosis
  • failed surgical bioprosthesis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Native Aortic Stenosis Cohorts:

  1. The subject is a candidate for TAVR using the DurAVR® THV System, and a SAPIEN series THV system or an Evolut series THV System.
  2. The local Heart Team agrees that the subject has an appropriate indication for, and will benefit from, TAVR due to native calcific valve severe aortic stenosis.
  3. Subject understands the study requirements and the treatment procedure and provides written .

ViV Registry Cohort:

  1. Severe degeneration of a surgically implanted aortic bioprosthetic valve.
  2. Subject requires aortic valve replacement and is high surgical risk and is indicated for TAVR Valve-in-Valve procedure as determined by the Heart Team.
  3. Subject understands the study requirements and the treatment procedure and provides written informed consent.

Exclusion criteria

Exclusion Criteria:

Native Aortic Stenosis Cohorts:

  1. Native aortic annulus size unsuitable for study THVs ( or control) based on CT imaging analysis.
  2. Access vessel characteristics that would preclude safe placement of the introducer sheath (investigational or control).
  3. Evidence of an acute myocardial infarction 30 days before randomization.
  4. AV is unicuspid, Type 0 bicuspid, or is non-calcified.
  5. Severe total aortic regurgitation
  6. Severe mitral or tricuspid regurgitation or ≥ moderate mitral stenosis.
  7. Pre-existing mechanical or bioprosthetic valve in any position.
  8. Untreated coronary artery disease (CAD) requiring revascularization.
  9. Cardiac imaging evidence of intracardiac mass, thrombus, or vegetation.
  10. Active bacterial endocarditis in the last 3 months.
  11. Estimated (after TAVR) \<12 months.
  12. Subject is not a candidate for both arms (investigational and control) of the study.
  13. Subject belongs to a vulnerable population

ViV Registry Cohort:

  1. Anatomy precluding safe placement of DurAVR THV.
  2. Pre-existing prosthetic heart valve in the mitral, tricuspid or pulmonary position.
  3. Severe mitral or tricuspid regurgitation or ≥ moderate mitral stenosis
  4. Cardiac imaging evidence of intracardiac mass, thrombus or vegetation.
  5. Failing surgical aortic bioprosthesis is unstable, rocking, or not structurally intact.
  6. Evidence of an acute myocardial infarction ≤ 30 days before the intended treatment.
  7. Untreated clinically significant coronary artery disease (CAD) requiring revascularization.
  8. Need for emergency surgery for any reason
  9. GI bleeding within the past 3 months.
  10. Active bacterial endocarditis in the last 3 months.
  11. Estimated life expectancy (after TAVR) \<12 months.
  12. Subject belongs to a vulnerable population.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Care provider)
Enrollment
1,650 participants (estimated)

Study arms

  • Experimental
    DurAVR THV

    DurAVR® THV implantation

    Device: TAVR with DurAVR® THV

  • Active comparator
    Control

    SAPIEN THV series or the Evolut THV series implantation

    Device: TAVR with SAPIEN THV series or the Evolut THV series

Interventions

  • DeviceTAVR with DurAVR® THV

    Transcatheter aortic valve replacement (TAVR)

  • DeviceTAVR with SAPIEN THV series or the Evolut THV series

    Transcatheter aortic valve replacement (TAVR)

06

What researchers measure

Primary outcomes

  1. Composite of all-cause mortality, all stroke and cardiovascular hospitalization

    Composite of all-cause mortality, all stroke and cardiovascular hospitalization

    Time frame: 1 Year

Secondary outcomes

  1. All-cause mortality

    Mortality from any cause will by collected by tracking patient's living status via medical record

    Time frame: 30 Days

  2. Disabling stroke according to VARC-3 Guidelines

    The precise categorization is outlined in the Valve Academic Research Consortium-3 (VARC-3) criteria.

    Time frame: 30 Days

  3. Life-threatening bleeding according to VARC-3 Guidelines

    The precise categorization is outlined in the Valve Academic Research Consortium-3 (VARC-3) criteria.

    Time frame: 30 Days

  4. Major vascular complication according to VARC-3 Guidelines

    The precise categorization is outlined in the Valve Academic Research Consortium-3 (VARC-3) criteria.

    Time frame: 30 Days

  5. Acute Kidney Injury (Stage III or IV) according to VARC-3 Guidelines

    The precise categorization is outlined in the Valve Academic Research Consortium-3 (VARC-3) criteria.

    Time frame: 30 Days

Other outcomes

  1. Mean Aortic Valve (AV) Gradient

    Mean Aortic Valve pressure gradient in mm Hg

    Time frame: 30 Days and 1 Year

  2. Valve-related dysfunction requiring a repeat procedure

    New intervention due to the valve not properly functioning

    Time frame: 30 Days and 1 Year

  3. Doppler Velocity Index (DVI)

    Doppler Velocity Index

    Time frame: 30 Days and 1 Year

  4. Non-Structural Valve Dysfunction

    Any abnormality, not intrinsic to the prosthetic valve, resulting in the valve not properly functioning

    Time frame: 30 Days and 1 Year

  5. Prosthesis-Patient Mismatch

    Calculated in percentage

    Time frame: 30 Days and 1 Year

  6. Aortic Regurgitation (AR)

    AR grading: None/Trace, Mild, Moderate, Severe

    Time frame: 30 Days and 1 Year

  7. New Permanent Pacemaker Implantation (PPI)

    New pacemaker implantation in subjects experiencing conduction abnormalities

    Time frame: 30 Days and 1 Year

  8. New York Heart Association (NYHA) Class

    NYHA Class graded as I, II, III or IV

    Time frame: 30 Days and 1 Year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Dec 2027, 26 months after the start.

Of 111 industry-sponsored interventional studies with no phase under Aortic Valve Stenosis, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 54. This study's planned 26 months is below that.

Counting every sponsor, half of 288 studies reached it within 33 months; a quarter within 18 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 5, 2025
First posted
Sep 26, 2025
StartActual
Oct 21, 2025
Primary completionEst.
Dec 2027
CompletionEst.
Mar 2038
Last update
Jul 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07194265
Lead sponsor
Anteris Technologies Ltd.
Responsible party
Sponsor
First posted
Sep 26, 2025
Start date
Oct 21, 2025
Primary completion
Dec 2027 (estimated)
Completion
Mar 2038 (estimated)
Last update
Jul 15, 2026

Study contacts

Emily Neumann
Contact
ENeumann@anteristech.com
+1 414 550 7619

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion